ADMS - Adamas Pharmaceuticals, Inc.

NasdaqGM - NasdaqGM Real Time Price. Currency in USD
8.61
-0.06 (-0.69%)
At close: 4:00PM EST
Stock chart is not supported by your current browser
Previous Close8.67
Open8.71
Bid0.00 x 2900
Ask0.00 x 900
Day's Range8.48 - 8.88
52 Week Range7.42 - 44.00
Volume268,440
Avg. Volume689,262
Market Cap235.359M
Beta (3Y Monthly)2.87
PE Ratio (TTM)N/A
EPS (TTM)-5.10
Earnings DateNov 1, 2017 - Nov 6, 2017
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est36.60
Trade prices are not sourced from all markets
  • GlobeNewswire13 days ago

    Adamas Announces New Employment Inducement Grant

    Adamas Pharmaceuticals, Inc. (ADMS) today announced that the compensation committee of the company’s board of directors granted four new employees the option to purchase an aggregate of 35,366 shares of the company’s common stock, at a per share exercise price of $9.56, the closing trading price on January 8, 2019, and restricted stock units to acquire 5,910 shares of the company’s common stock. The stock options and restricted stock units vest over four years and were granted pursuant to the Adamas Pharmaceuticals, Inc. 2016 Inducement Plan, which was approved by the company's board of directors in March 2016 under Rule 5653(c)(4) of the Nasdaq Global Market for equity grants to induce new employees to enter into employment with the company.

  • Here's Why These Small-Cap Pharma Stocks Lost as Much as 45% in December
    Motley Fool14 days ago

    Here's Why These Small-Cap Pharma Stocks Lost as Much as 45% in December

    A volatile stock market dished out an extra dose of punishment to riskier assets, including these three small-cap pharma companies.

  • GlobeNewswire18 days ago

    Adamas Provides Preliminary Fourth Quarter and Full-Year 2018 GOCOVRI™ Sales Results and Outlines Key Priorities for 2019

    Adamas Pharmaceuticals, Inc. (ADMS), a fully-integrated pharmaceutical company pioneering time-dependent medicines for central nervous system (CNS) disorders, today outlined key business priorities for 2019 and provided preliminary 2018 sales results for GOCOVRI™ (amantadine) extended release capsules.  GOCOVRI is the first and only FDA-approved medicine indicated for the treatment of dyskinesia in patients with Parkinson’s disease receiving levodopa-based therapy and only medication clinically proven to reduce both dyskinesia and OFF in that population.

  • Benzingalast month

    The Daily Biotech Pulse: Pfizer-Glaxo Set Up Consumer Health Care Venture, New Patent For Adamas

    Here's a roundup of top developments in the biotech space over the last 24 hours. No biotech stocks hit 52-week highs Tuesday. Down In The Dumps (Biotech stocks hitting 52-week lows on Dec. 18) Accelerate ...

  • GlobeNewswirelast month

    Adamas Announces Issuance of New U.S. Patent Covering GOCOVRI™

    The USPTO has now issued a total of 14 patents from three separate patent families in the GOCOVRI patent portfolio, which now has patents expiring from 2025 to 2034.  The ‘971 patent will be listed in the U.S. Food and Drug Administration’s (FDA) Approved Drug Products with Therapeutic Equivalence Evaluations, commonly known as the Orange Book. GOCOVRI (amantadine) extended release capsules is the first and only FDA-approved medicine indicated for the treatment of dyskinesia in patients with Parkinson’s disease receiving levodopa-based therapy, with or without concomitant dopaminergic medications.

  • Is Adamas Pharmaceuticals Inc (ADMS) A Good Stock To Buy?
    Insider Monkeylast month

    Is Adamas Pharmaceuticals Inc (ADMS) A Good Stock To Buy?

    Insider Monkey has processed numerous 13F filings of hedge funds and famous investors to create an extensive database of hedge fund holdings. The 13F filings show the hedge funds and investors’ positions as of the end of the third quarter. You can find write-ups about an individual hedge fund’s trades on numerous financial news websites. […]

  • Why Adamas Pharmaceuticals, Inc. Stock Continued to Slide in November
    Motley Foollast month

    Why Adamas Pharmaceuticals, Inc. Stock Continued to Slide in November

    Adamas Pharmaceuticals' valuation took yet another hit last month. Here's why.

  • Thomson Reuters StreetEvents2 months ago

    Edited Transcript of ADMS earnings conference call or presentation 1-Nov-18 8:30pm GMT

    Q3 2018 Adamas Pharmaceuticals Inc Earnings Call

  • GlobeNewswire2 months ago

    Adamas to Present at Three November Investor Conferences

    EMERYVILLE, Calif., Nov. 09, 2018 -- Adamas Pharmaceuticals, Inc. (Nasdaq: ADMS), a fully-integrated pharmaceutical company pioneering time-dependent medicines for central.

  • GlobeNewswire3 months ago

    Factors of Influence in 2018, Key Indicators and Opportunity within Apptio, Adamas Pharmaceuticals, NEXEO SOLUTIONS, Computer Programs and, Solaris Oilfield Infrastructure, and SPX — New Research Emphasizes Economic Growth

    NEW YORK, Nov. 08, 2018 -- In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors,.

  • The Probable Reason Why Adamas Pharmaceuticals Inc. Is Down Big Today
    Motley Fool3 months ago

    The Probable Reason Why Adamas Pharmaceuticals Inc. Is Down Big Today

    Shares fall hard after the company reports good news. What's going on?

  • Associated Press3 months ago

    Adamas: 3Q Earnings Snapshot

    The Emeryville, California-based company said it had a loss of $1.22 per share. The results beat Wall Street expectations. The average estimate of six analysts surveyed by Zacks Investment Research was ...

  • GlobeNewswire3 months ago

    Adamas Reports Third Quarter 2018 Financial Results

    GOCOVRI™ (amantadine) extended release capsules sales increased to $10.6 million for the third quarter, with ~4,740 fulfilled prescriptions EMERYVILLE, Calif., Nov. 01, 2018.

  • Benzinga3 months ago

    The Daily Biotech Pulse: AbbVie's Leukemia Drug Trial Meets Endpoint, Denali Strikes Collaboration Deal

    Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peak (Biotech stocks hitting 52-week highs on Nov. 1) Merck & Co., Inc. (NYSE: MRK )(announced FDA approval ...

  • GlobeNewswire3 months ago

    Adamas to Announce Third Quarter 2018 Financial Results and Host Conference Call on November 1, 2018

    Adamas Pharmaceuticals, Inc. (ADMS), a fully-integrated pharmaceutical company pioneering time-dependent medicines for central nervous system disorders, today announced that it will report third quarter 2018 financial results on Thursday, November 1, 2018, after market close. Subsequently, Adamas’ management team will host a conference call and webcast at 4:30 p.m. Eastern Time to discuss the financial results and provide a corporate update. The conference call can be accessed by dialing 844-215-3280 for participants in the U.S. or Canada and 484-747-6383 for international callers.

  • Reuters3 months ago

    China cutting rare earth output, unnerving global manufacturers

    LONDON/HOUSTON Oct 24 (Reuters) - The Chinese government is limiting domestic production of rare earth minerals in the second half of the year, a move likely to crimp international exports and send prices for the critical materials soaring, according to data from Adamas Intelligence. China is by far the world's largest producer and consumer of rare earths, a group of 17 elements used to make electric vehicles and consumer electronics. The move is already forcing manufacturers to scour the globe for alternative supplies.

  • Why Adamas Pharmaceuticals, Inc. Stock Sank in September
    Motley Fool3 months ago

    Why Adamas Pharmaceuticals, Inc. Stock Sank in September

    Adamas' steady march lower continued in September. Here's why.

  • Simply Wall St.4 months ago

    When Can We Expect A Profit From Adamas Pharmaceuticals Inc (NASDAQ:ADMS)?

    Adamas Pharmaceuticals Inc’s (NASDAQ:ADMS): Adamas Pharmaceuticals, Inc. discovers, develops, and sells therapies for chronic neurologic disorders. The US$543m market-cap posted a loss in its most recent financial year of -US$89m Read More...

  • A Financial Overview of Supernus Pharmaceuticals in September
    Market Realist4 months ago

    A Financial Overview of Supernus Pharmaceuticals in September

    In the second quarter, Supernus Pharmaceuticals (SUPN) reported net revenues of $99.5 million compared to $75.8 million in the second quarter of 2017. In the first half, Supernus Pharmaceuticals generated net revenues of $190.0 million compared to $133.4 million in the first half of 2017.

  • Supernus Pharmaceuticals Garners 89% ‘Buy’ Ratings in September
    Market Realist4 months ago

    Supernus Pharmaceuticals Garners 89% ‘Buy’ Ratings in September

    On September 11, Supernus Pharmaceuticals (SUPN) stock closed at $48.80, up 1.99% from its closing price of $47.85 on September 10. The company’s September 11 stock price was 26.0% below its 52-week high of $61.25 on June 29. Supernus Pharmaceuticals hit its 52-week low of $33.30 on November 7, 2017.